One of the most common cancers occurring worldwide is Bladder Cancer. In 2018 there were 549393 cases of bladder cancer along with 199922 deaths. Early detection is essential to prevent the disease progression and improve the patient’s survival and quality of life. In this study, we assessed the performance of Nuclear Matrix Protein 22 (NMP22) for the early detection of bladder cancer. We searched kinds of literature using PubMed, MEDLINE, and Cochrane Library. The population was Bladder cancer patients undergoing the NMP22 test. The diagnostic accuracy of the NMP22 was evaluated through sensitivity, specificity, Positive Likelihood Ratio (PLR), Negative Likelihood Ratio (NLR), Diagnostic Odds Ratio (DOR), and Area Under Curve (AUC). Heterogeneity was analyzed using subgroup analyses. Egger test was used to detect publication bias. Stata 14.0 and Review Manager were used to analyze the data. The results showed sensitivity was 0.64 (95% CI = 0.57 to 0.70), specificity was 0.84 (95% CI = 0.79 to 0.88), PLR was 4.1 (95% CI = 3.1 to 5.4), NLR was 0.43 (95% CI = 0.36 to 0.50), DOR was 10 (95% CI = 7 to 14), and AUC was 0.81 (0.77 – 0.84). NMP22 had high sensitivity and specificity in ASIA compared to other regions. Egger’s test showed that no publication bias existed (P = 0.36). NMP22 test could become an early detection method for bladder cancer because of its high specificity. The NMP22 test may be appropriate for detecting bladder cancer, but it cannot replace cystoscopy.